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Abstract 
Background: Attentional bias (AB) is implicated in the development and maintenance of 
substance dependence and in treatment outcome. We assessed the effects of attentional bias 
modification (ABM), and the relationship between AB and treatment adherence in opiate 
dependent patients. Method: An independent groups design was used to compare 23 opiate 
dependent patients with 21 healthy controls. Participants completed an AB task before either 
a control or an ABM task designed to train attention away from substance-related stimuli. 
Pre- and post-ABM AB and craving were assessed to determine any changes. Relationships 
between treatment adherence (‘using on top’ of prescribed opiates or not) and AB, craving 
and psychopathology were also examined. Results: There was no baseline difference in AB 
between patients and controls, and no significant effect of ABM on AB or substance craving. 
However, treatment adherent patients who did not use illicit opiates on top of their prescribed 
opiates had statistically significantly greater AB away from substance-related stimuli than 
both participants using on top and controls, and reported significantly lower levels of craving 
than non-treatment adherent patients. Conclusion: While we did not find any significant 
effects of ABM on AB or craving, patients who were treatment adherent differed from both 
those who were not and to controls in their attentional functioning and substance craving. 
These findings are the first to suggest that AB may be a within-treatment factor predictive of 
adherence to pharmacological treatment and potentially to recovery in opiate users.  
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1.1 Introduction 
Attentional bias (AB) – where disorder-related stimuli become the focus of one's 
attention – has been consistently demonstrated for substance-related stimuli in substance 
users relative to non-users (Wiers and Stacy, 2006; Field and Cox, 2008). Furthermore, AB is 
associated with craving in addiction (Field et al., 2006), is positively correlated with 
frequency of substance use (Townsend and Duka, 2001; Morgan et al., 2008; 2010) and has 
been linked to relapse in individuals abstaining from substance use (Cox et al., 2002; 
Marissen et al., 2006). 
Consequently, AB features as a key component of many recent theoretical models of 
addiction (Ryan, 2002; Franken, 2003; Wiers and Stacy, 2006), where it is awarded a central 
role in the development and maintenance of substance use. These models suggest a reciprocal 
causal relationship between craving and AB. It follows, therefore, that direct manipulation of 
AB should produce meaningful changes in clinically relevant variables such as substance 
craving and frequency of substance use. 
One approach to addressing this question has used the modified visual probe task, 
which aims to experimentally manipulate AB (MacLeod et al., 2002). Here, the task is 
modified by adjusting task contingencies, so that probes replace neutral images more often 
than substance-related images thereby training participants’ attention towards neutral stimuli. 
To date, the modified visual probe paradigm has been applied to tobacco smokers 
(e.g. Attwood et al., 2008) and to alcohol users both in the community and the clinic 
(Schoenmakers et al., 2007; 2010). These studies typically suggest that AB can be readily 
modified. However, mixed findings have been reported for the broader effects of ABM on 
craving and substance use behaviour (e.g. Field et al., 2007; Attwood et al., 2008). For 
example, in studies with healthy controls, rather than clinically relevant benefits (when 
training away from substance cues), it appears more common to induce ‘adverse’ effects 
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(when training towards substance cues) such as increased subjective craving (Field et al., 
2007, for participants aware of experimental contingencies only; Attwood et al., 2008, in men 
only).  
There has been only one ABM study to date examining a treatment-seeking, clinical 
sample (alcohol dependent patients; Schoenmakers et al., 2010). Importantly, this study did 
report broader beneficial effects of ABM away from substance-related stimuli: training 
effects generalised to novel substance-related stimuli (i.e. to stimuli other than those used 
during ABM) and participants were also discharged from treatment significantly earlier than 
the control group. However, while successful generalisation to novel stimuli was reported 
here, other studies have failed to demonstrate this effect (Schoenmakers et al., 2007). 
Although only a preliminary study, Schoenmakers et al. (2010) provide some 
tentative yet important evidence of clinically-relevant benefits of ABM. Given that AB is 
positively correlated with frequency of substance use, it may be that AB is more modifiable 
in clinical samples, and as Field et al. (2013) have pointed out, the inconsistent findings 
regarding ABM in substance use to date is possibly because almost all studies have used non-
clinical, student samples. 
The present study had a primary and secondary aim.  Primarily, we set out to 
investigate the effects of a single session of ABM on AB, craving, and frequency of 
substance use using a modified visual probe task in opiate dependent participants receiving 
opiate substitute treatment. No study to date has investigated ABM in this population. The 
secondary aim was based on our previous finding in a similar patient population that AB 
away from substance-related stimuli was positively correlated with length of abstinence in 
ex-opiate users (Constantinou et al., 2010). This suggestion of a link between AB and 
treatment progress therefore led us to also explore in the present study the relationship 
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between AB and a key aspect of treatment adherence: whether participants were using illicit 
opiates on top of their prescribed opiates. 
Specifically, we hypothesised that: 1) Opiate dependent participants would show a 
significant baseline AB toward substance-related stimuli relative to non-substance using 
controls. 2) Participants receiving ABM away from substance-related stimuli would show 
decreased AB and substance craving following ABM compared with those receiving the 
control visual probe task.  In addition, we explored the differences between treatment 
adherent and non-treatment adherent participants in the opiate using group and controls on 
AB, substance craving and other clinically relevant measures. 
 
2.1 Method 
2.2 Design and Participants 
An independent groups design was used to compare 23 current opiate users (patient 
group) with 21 participants (control group) who did not use illicit substances.  
Patient group participants were required to be opiate users prescribed a substitute 
medication as part of their treatment within National Health Service (NHS) drug services. In 
the NHS treatment typically includes substitute opiate prescription and regular meetings with 
a key worker who provides advice and support. Patients were recruited via their key workers 
and advertisements. Exclusion criteria were a current diagnosis of a psychotic disorder or 
alcohol dependence; use of illicit substances and alcohol on testing days. 
To control for the relatively high levels of depression and anxiety in opiate users 
(Regier et al., 1998), control participants were recruited from an NHS primary care mental 
health service (Improving Access to Psychological Therapies; IAPT). However, to address 
the gender imbalance of patients comprising substance misuse (majority male) and IAPT 
(majority female) services, we also recruited healthy male participants from the local 
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community. The final control group consisted of 10 participants recruited from IAPT, and 11 
healthy control participants. IAPT participants were recruited via poster advertisements or a 
database of the service’s patients who expressed interest in research. Healthy participants 
were recruited via University College London’s online community participant recruitment 
service. Exclusion criteria for controls were a history of or current illicit substance use, 
alcohol dependence or psychotic disorder.  
The study was approved by the NHS National Research Ethics Committee, Surrey, 
and the UCL Psychology Ethics Committee. Written, informed consent was obtained from all 
participants. Patients were paid £20 and controls £10 for participation.   
 
2.3 Materials and Measures  
2.3.1 Stimuli 
Stimuli were 44 picture pairs (Figure 1). Forty pairs, each matched for visual 
complexity and composition, contained one opiate-related (e.g. spoons, needles, lighters, 
heroin-like substance) and one non-opiate related (neutral; e.g. forks, pencils) image. The 
remaining four pairs contained neutral images only. The 40 opiate-neutral pairs were divided 
into five sets of eight.   
[Figure 1 about here] 
 
2.3.2 Substance use 
The Timeline Followback method (Sobell & Sobell, 1996) was used to gather substance 
use (including alcohol and tobacco) over the past 28 days.  
 
2.3.3 Questionnaire measures 
6 
 
Baseline measures comprised the Patient Health Questionnaire (PHQ-9; Kroenke et 
al., 2001), Beck Depression Inventory-II (BDI-II; Beck et al., 1996, Generalized Anxiety 
Disorder-7 (GAD-7; Spitzer et al., 2006), and the Barratt Impulsiveness Scale-11 (BIS-11; 
Patton et al., 1995); on each of these, higher scores reflect greater symptomology. Subjective 
craving was assessed by a three 10 cm Visual Analogue Scales (VAS; Bond & Lader, 1972): 
“I would like to use drugs,” “I want to use drugs,” and “I have an urge to use drugs,” each 
anchored “Not at all” and “Extremely”.  
 
2.4 Procedure 
There were 3 separate testing sessions for the patient group: Session 1 (day 0), 
Session 2 (day 8) and Session 3 (day 28).  For controls, only session 1 was attended as they 
would not be expected to derive any clinical benefit from ABM.  Sessions 1, 2 and 3 took 
approximately 90, 15 and 20 minutes to complete, respectively. 
On Session 1, eligible participants were randomly assigned to receive either ABM 
away from substance-related stimuli (ABM-away) or a standard visual probe control task 
(ABM-control). The day before each test sessions, all participants were reminded not to 
consume illicit substances or alcohol on the test day. On each test day, they were asked if 
they had consumed any, and appointments rearranged accordingly (one participant); no 
participant was visibly intoxicated. Participants next completed questionnaires and a 28-day 
substance use history.  
Baseline assessment of AB (AB-0) was then completed. This comprised a standard 
visual probe task. Each trial began with a fixation point (500ms). A pair of images then 
appeared on the left and right of the screen. Images appeared for either a short (200ms) or 
long (500ms) duration to assess automatic orienting and controlled attention processing 
respectively. Image pairs were then replaced by a probe (an arrow pointing upwards or 
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downwards) in the location of either the neutral or opiate-related image. The probe remained 
on screen until the participant responded to identify the probe type (upwards or downwards) 
by pressing one of two appropriate response keys as quickly and accurately as possible. 
Probes replaced the opiate-related and neutral images equally often. The right/left position of 
image type, probe location, and stimulus duration were all counterbalanced and inter-trial 
interval (250-500ms) was randomly determined.  Trials were displayed in a single block, with 
each pair presented eight times, producing 64 critical trials and 16 neutral trials. Trials were 
displayed in a new random order for each participant. 
Immediately afterwards participants completed either ABM-away or ABM-control. 
Stimuli consisted of Sets 1-4 of the opiate-neutral pairs.  Each pair was presented 16 times, 
producing 512 critical trials. Stimuli were presented in two equal blocks of 256 trials, with 
participants having the opportunity for a 5 minute break between blocks. For ABM-away and 
ABM-control, probes replaced neutral images on 100% and 50% of trials, respectively, and 
ABM-control was counterbalanced in the same manner as AB-away. Thus, the sole 
difference between the ABM-away and ABM-control tasks was the probe’s position. 
Following a 30-minute break, a further assessment of attentional bias (AB-1) and a 
VAS were then administered to re-assess AB and craving. AB-1 featured Sets 1 and 5, plus 
all four neutral-neutral image pairs, thus allowing the assessment of the effects of ABM on 
both familiar (Set 1 and two neutral pairs from AB-0) and novel (Set 5 and two unseen 
neutral pairs) stimuli. Each pair was presented eight times, giving 128 critical (64 familiar, 
and 64 novel) and 32 neutral (16 familiar, 16 novel) trials. The task was counterbalanced in 
the same way as AB-0. Stimuli were presented in a single block and displayed in a new 
random order for each participant. 
Control participants’ awareness of the experimental contingencies was assessed at the 
end of Session 1 by asking them (a) their views about the aim of the study; (b) whether they 
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detected any patterns in the probe location during the ABM task. ‘Aware’ participants 
correctly answered either question. Control participants were then debriefed and paid.  
Debriefing outlined the study aims in detail and the intended effects of the ABM task. They 
were told which group they had been randomised to, and those in the ABM-control group 
could complete the ABM-away task if they wished.  Their wellbeing was enquired about, and 
provision was in place for further support if required from the experimenters (MC, CW and 
CM) or from service staff.   
In Sessions 2 and 3 (patient participants only) further assessments of attentional bias 
(AB-2 and AB-3, both having the exact stimuli, specifications and counterbalancing as AB-1) 
were administered together with questionnaires In Session 3 an additional 28-day substance 
use history was taken, participants’ awareness was assessed and they were debriefed and 
paid. 
 
2.5 Statistical Analysis 
 For the visual probe data, trials were excluded i) with neutral-neutral stimulus pairs, 
ii) where a response error was made (3.3% of baseline trials, 3.5% over post-ABM 
assessments), or where reaction time (RT) was <200ms or >2000ms (2% baseline, 0.2% over 
post-ABM assessments). Within opiate-neutral stimulus pairs, attentional bias scores were 
calculated by subtracting mean RTs to probes that replaced opiate-related stimuli from mean 
RTs to probes that replaced neutral stimuli. A positive AB score therefore indicates AB 
towards opiate-related stimuli. 
Data from one patient participant were missing at Day 2 due to non-attendance (99% 
overall retention). Administrative error meant one patient’s (ABM-control) VAS data  were 
unavailable following the Session 1break. 
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Four groups (patient ABM-away and ABM-control; control ABM-away and ABM-
control) were compared with one way or repeated measures ANOVAs. Post-hoc comparisons 
were Bonferroni corrected t-tests. Investigation of treatment adherence (3 groups: treatment 
adherent patients, non-treatment adherent patients, controls) used Dunnett’s post-hoc 
comparisons with treatment adherent patients as the reference group. 
 
3.1 Results 
3.2 Participant Characteristics (see Table 1) 
 One-way ANOVAs which showed significant group differences in years of education 
[F(3, 40) = 6.68, p = .001], VAS ‘like’ [F(3, 40) = 4.83, p = .006], VAS ‘want’ [F(3, 40) = 
5.26, p = .004], VAS ‘urge’ [F(3, 40) = 6.09, p = .002], BDI-II [F(3, 40) = 4.56, p = .008], 
and PHQ-9 [F(3, 40) = 5.52, p = .003]. Post-hoc comparisons (Bonferroni) revealed that 
control participants allocated to ABM-control had significantly more years of education than 
patient participants allocated to ABM-away (p = .001) and to ABM-control (p = .014)[ VAS 
‘like’, VAS ‘want’ and VAS ‘urge’ were significantly greater in patient participants allocated 
to ABM-control than controls allocated to ABM-away (like: p = .015; want: p = .006; urge: p 
= .003) and to ABM-control (like: p = .019; want:  p = .022; urge: p = .006). The group 
difference in BDI-II was driven by patient participants allocated to ABM-away scoring 
significantly higher than controls allocated to ABM-control (p = .040); the difference in 
PHQ-9 reflected higher scores in patient participants allocated to ABM-control than controls 
allocated to ABM-control (p = .004).  
 
[Table 1 about here] 
 
3.3 Attentional Bias and ABM (Table 2)  
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At baseline, patient participants did not differ from controls on stimuli displayed for 
200ms [t(42) = -0.11, p = .912] or 500ms [t(42) = -1.92, p = .066].  
To assess the effects of ABM on AB, only AB scores for familiar stimuli were used 
from AB-1. AB scores of the 4 groups were compared using a mixed-design 4x2x2 ANOVA, 
with group as a between-subjects factor and within subjects factors of stimulus duration 
(200ms, 500ms) and time (AB-0, AB-1). The predicted interaction between group and time 
was non-significant [F(3, 40) = 0.82, p = .491, ŋp2 = .058, observed power = .211], and no 
other significant effects emerged.  
 
[Table 2 about here] 
 
3.4 Effects of ABM on AB and craving over Time for Patient Participants 
AB scores were analysed using the same 2x2x4 ANOVA; no significant main effects 
or interactions emerged. 
 VAS ‘like’, ‘want’ and ‘urge’ data were analysed separately using 2x3 ANOVAs, 
with a of ABM condition (2 levels: ABM-away, ABM-control) as between-subjects factor 
and a within-subjects factor of time (pre-ABM, post-ABM, after 30-minute delay).  No 
significant main effects or interactions emerged. 
 
3.5 Contingency Awareness 
 Only one control participant (allocated to ABM-away), and no patients, correctly 
identified the task contingency.   
 
3.6 Substance Misuse Treatment Adherence 
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At baseline, 12 patient participants reported that they used illicit opiates on top of 
their prescribed substitute, while 11 reported that they did not use on top.  
 
[Table 3 about here] 
 
These three groups (patients not using on top, patients using on top, controls) were 
compared on each variable in Table 3 using one-way ANOVAs. There were significant group 
differences in BDI-II [F(2, 41) = 7.01, p = .002], PHQ-9 [F(2, 41) = 8.59, p = .001], and BIS-
11 scores [F(2, 41) = 5.59, p = .007]. Post-hoc comparisons (Bonferroni) indicated that 
participants using on top had significantly greater BIS-11 (p = .005) and PHQ-9 (p = .001) 
scores than controls. BDI-II scores were higher than controls for participants using on top (p 
= .005) and not using on top (p = .028).   
There were significant baseline differences in VAS ‘like’ [F(2, 41) = 15.53, p < .001], 
‘want’ [F(2, 41) = 13.39, p < .001] and ‘urge’ [F(2, 41) = 14.71, p < .001]. In all cases 
participants using on top reported higher cravings than those who did not use on top (like: p = 
.001; want: p = .006; urge: p = .001) and controls (all subscales: p < .001). Methadone dose 
did not differ between participants who did and did not use on top [t(15) = 1.27, p = .222]. 
Table 4 displays the baseline AB scores for patient participants using on top, not 
using on top and control participants. A 3x2 ANOVA, with a between-subjects factor of 
group (patients not using on top, patients using on top, controls), and a within subjects factors 
of stimulus duration (200ms, 500ms) revealed a significant main effect of group [F(2, 41) = 
3.80, p = .031, ŋp2 = 0.156, observed power = .659; Figure 2]  Post-hoc tests (Dunnett’s) 
showed that participants not using on top had significant bias away from opiate-related 
stimuli and towards neutral stimuli to a greater extent than those using on top (p = .043) and 
controls (p = .027). No other significant effects emerged.   
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[Table 4 & Figure 2 about here] 
 
  Table 5 displays the number of patient participants using other illicit and licit 
psychoactive substances.  Small numbers precluded statistical analyses but 7/12 of those 
using illicit opiates on top also used crack cocaine but this was not the case with those not 
using on top.  
 
[Table 5 about here] 
 
4.1 Discussion 
Our hypotheses related to our primary aim in this study were not supported. 
Specifically, there was no baseline difference in attentional bias between opiate dependent 
patients and controls, nor was there any significant effect of ABM on AB or substance 
craving. Therefore, the present findings do not lend support to the use of ABM as a possible 
adjunct to treatment. However, the weaknesses of the present study, discussed below, should 
be borne in mind and improvements in future studies’ design may provide more hopeful 
results, as did Schoenmakers et al. (2010). 
However, analyses related to our secondary aim revealed a significant relationship 
between attentional bias away from substance-related stimuli and adherence to substance 
misuse treatment (using additional illicit opiates, as well as prescribed methadone or 
buprenorphine). Participants not using illicit opiates showed an attentional bias away from 
substance-related stimuli and towards neutral stimuli, relative to both participants using on 
top and control participants. This resonates with Constantinou et al.’s (2010) finding that ex-
opiate users in rehabilitation showed a bias away from substance-related stimuli that 
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correlated positively with their length of abstinence. It is also in keeping with a recent finding 
reported by Peuker and Bizarro (2014) who found attentional avoidance of smoking-related 
stimuli in former smokers, and with Schoenmakers et al.’s (2010) findings where AB away 
from alcohol-related stimuli induced by ABM was associated with earlier discharge from 
treatment for alcohol dependent inpatients. Our results may also extend these findings to 
specify within treatment differences (i.e. simultaneous use of illicit opiates) that may be 
predictive of “recovery” (i.e. ex-opiate user status). However, this would require further 
investigation. For example, although self-reported drug use, which our study relied upon, has 
respectable reliability and validity in similar populations to those from which we recruited 
(e.g. Darke, 1998), urinary drug screens could be used to objectively verify treatment 
adherence to provide better support to this idea. 
In addition, participants using on top had significantly greater craving for substances 
(as indexed by substance liking, wanting and urge to use) at baseline than participants not 
using on top, as well as controls. Further, those using on top scored significantly higher at 
baseline than controls on depressive symptomatology (PHQ-9; BDI-II) and impulsivity 
(BIS). Those not using on top only differed from controls on depression as indexed by BDI-II 
scores and showed similar scores on all other self-rated measures including substance 
craving. Given that there was no difference in self-reported levels of depression, anxiety or 
impulsivity between the two patient (treatment adherent, and non-treatment adherent) groups, 
and the only differences found were with respect to AB and self-reported craving, a possible 
clinical implication arises in that AB could potentially be used as a psychological measure of 
treatment engagement. However, this would require closer examination in future studies, for 
example through a more comprehensive assessment of anxiety (Cisler & Koster, 2010). 
The lack of significant results in relation to our primary hypotheses may have arisen 
for a number of reasons. The most significant of these is the major limitation of our study, 
14 
 
namely low statistical power. This is largely a product of the fact that we investigated a 
clinical sample of opiate dependent patients, of which recruitment is challenging. However, 
we did achieve our required sample size based on our a priori power calculation, although 
this was based on effect size estimates also generated from a relatively small clinical sample 
(Schoenmakers et al., 2010) and thus was also likely affected by a similar issue. As small 
samples can bias estimates of effect size, it is possible that there was a true effect of ABM in 
our sample, except our study was not adequately powered to detect it. It is also important to 
highlight, of course, that the implications of our findings outlined above need to be 
considered in light of this limitation. Whilst acknowledging the limitation of power, the 
treatment-seeking, opiate dependent group we recruited is a key strength of this study, and an 
important criterion for assessing the clinical relevance of AB and its modification.   
Given that we recruited opiate using participants, we specifically designed our ABM 
task to be brief (e.g. compared to Schoenmakers et al., 2010), taking approximately 20-25 
minutes to complete including a short break half-way through the task. Advantages of this 
approach include minimisation of possible boredom and errors, although fewer trials might 
have limited the efficacy of the intervention. 
The fact that we found no baseline difference in AB between opiate users and controls 
is also interesting. This may partly be due the relative novelty of opiate-related stimuli 
compared to neutral stimuli for control participants. Although visual attributes of the two 
types of stimuli were matched, novelty of substance-related images to a non-substance using 
population is hard to control. It is also noteworthy that the opiate-related stimuli used in the 
AB tasks consisted of heroin and its paraphernalia, but not of methadone or buprenorphine.  
Our findings would benefit from replication in future studies with greater statistical 
power. Future studies may also wish to examine the association between AB and craving and 
methadone or buprenorphine dose at baseline, and the differences in licit and illicit substance 
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use between patients who do and do not use illicit opiates on top. It may also be useful to 
include images of methadone and buprenorphine as stimuli in all AB tasks.  
In summary, our findings suggest that opiate dependent patients are not a 
homogenous group since, depending on their illicit opiate use, they differed in attentional 
bias and craving. Our findings are the first to suggest that attentional bias may reflect 
adherence to pharmacological treatment in opiate users. 
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Table 1 
Mean (SD) of demographic and baseline variables for each group 
 Patient group  Control group  
 ABM-away 
(n=11) 
ABM-control 
(n=12) 
 ABM-away 
(n=11) 
ABM-control 
(n=10) p
a 
 
Age 
 
43.91 (6.77) 
 
45.17 (8.89) 
 
 
41.00 (8.53) 
 
38 (6.68) 
 
Gender (M:F) 10:1 10: 2  8:3 7:3  
Years of education 11.91 (1.64) 13.33 (2.81)  14.00 (4.02) 17.30 (2.32) * 
Methadone dose 62.75 (25.78) 60.56 (36.70)  - -  
Buprenorphine dose 9.33 (2.31) 7.33 (7.57)  - -  
n using illicit opiates 4 8  - -  
BDI-II 22.7 (13.9) 21.8 (10.3)  10.6 (13.1) 8.4 (7.0) * 
PHQ-9 10.7 (6.3) 13.3 (6.2)  6.4 (7.5) 3.6 (3.7) * 
GAD-7 9.1 (7.4) 7.3 (6.1)  4.6 (5.9) 6.3 (3.9)  
BIS 66.9 (11.4) 72.9 (19.9)  58.6 (13.5) 59.0 (8.3)  
VAS ‘like’ 2.1 (2.3) 3.4 (3.5)  0.4 (0.7) 0.4 (0.7) * 
VAS ‘want’ 1.8 (2.0) 3.1 (3.1)  0.1 (0.2) 0.5 (1.0) * 
VAS ‘urge’ 1.3 (1.7) 3.3 (3.4)  0.1 (0.2) 0.3 (0.7) * 
Note: As is typical of this patient group, most patients were White-British men. ABM-away patient participants: 
8 were prescribed methadone, 3 buprenorphine. ABM-control 9 patient participants were prescribed methadone, 
versus,  3, buprenorphine.  
a *p<.01 
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Table 2 
Mean (SD) attentional bias pre- and post-ABM (i.e. AB-0 and AB-1) for patient and control 
participants in each experimental group. 
 
 Patient group  Control group 
 ABM-away 
(n=11) 
ABM-control 
(n=12) 
 ABM-away 
(n=11) 
ABM-control 
(n=10) 
 
Pre-ABM (200ms) 
-7.45 (102.40) -10.49 (75.25)  4.21 (44.66) -18.43 
(63.52) 
Pre-ABM (500ms) -26.10 (96.06) -23.10 (74.15)  4.26 (33.93) 18.75 (26.88) 
Post-ABM (200ms) -2.53 (31.74) -11.76 (56.24)  -3.92 (31.00) 12.91 (34.85) 
Post-ABM (500ms) 23.68 (54.24) -5.70 (52.07)  -16.80 
(44.92) 
5.32 (29.07) 
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Table 3 
Clinically relevant variables at baseline for patient participants who were using on top, not 
using on top, and controls. 
 Patient group  Control group (c)  
 Not using on top (a) 
(n=11) 
Using on top (b) 
(n=12) 
 
(n=21) pa 
Methadone dose 74.33 (44.14)b 54.64 (20.48)c  -  
BDI-II 21.1 (7.4) 23.3 (15.1)  9.6 (10.5) 2, 3 
PHQ-9 10.1 (3.6) 13.9 (7.6)  5.1 (6.0) 2 
GAD-7 7.1 (6.0) 9.1 (7.3)  5.4 (5.0)  
BIS-11 64.4 (14.0) 75.3 (17.1)  58.8 (11.0) 2 
VAS ‘like’ 1.2 (1.6) 4.2 (3.3)  0.4 (0.6) 1, 2 
VAS ‘want’ 1.2 (1.7) 3.7 (2.9)  0.3 (0.7) 1, 2 
VAS ‘urge’ 0.8 (1.47) 3.7 (3.2)  0.2 (0.5) 1, 2 
Note: Buprenorphine dose is not reported due to low numbers of participants in the non-adherent group (n=1).  
a 1 = a vs b, p < .050; 2 = b vs c, p < .050; 3 = a vs c, p < .050 
b n=6; the 5 other participants in this group were prescribed buprenorphine  
c n=11; the 1 other participant in this group was prescribed buprenorphine 
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Table 4 
Baseline mean (SD) attentional bias scores for patient participants using on top, not using on 
top and controls. 
 
 Patient group  Control group (c)  
 Not using on top (a) 
(n=11) 
Using on top (b) 
(n=12) 
 
(n=21) pa 
AB at 200ms -31.63 (97.98) 11.68 (74.13)  -6.57 (54.28)  
AB at 500ms -46.56 (54.88) -4.34 (101.11)  11.16 (30.91)  
AB (collapsed) -37.48 (52.98) 3.23 (53.35)  1.82 (26.31) 1, 3 
a 1 = a vs b, p < .050; 2 = b vs c, p < .050; 3 = a vs c, p < .050 
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Table 5 
Number of patient participants using illicit substances on top of their prescribed substitute, 
including mean quantity used over the past 28 days. 
 Not using on top (N=11)  Using on top (N=12) 
 n using Mean (SD)  n using Mean (SD) 
Illicit opiates (g/day) - -  12 0.09 (0.09) 
Crack cocaine (g/day) 0 -  7 0.07 (0.06) 
Cannabis (n joints/day) 2 1.45 (2.00)  4 1.00 (0.96) 
Alcohol (units/week) 4 7.00 (9.42)  3 43.67 (14.15) 
Benzodiazepines (mg/day) 5a, b 6.46 (7.87)  3c, d 19.00 (0.00) 
a 1 participant was on a reducing prescription for diazepam 
b Quantity used data missing for 1 participant who reported using 
c 2 participants were on a reducing prescription for diazepam 
d Quantity used data missing for 2 participants who reported using 
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Figure 1: Examples of opiate-neutral picture pair stimuli used in the visual probe tasks. 
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Figure 2: Mean attentional bias (plus standard error) at baseline for patient  
participants not using on top, using on top and controls. 
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